Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH Pharma prize winner of Deloitte Technology Fast 50 2014 Rhône-Alpes Bourgogne Auvergne
Lyon, France, November 14, 2014 – ERYTECH (Euronext Paris: FR0011471135 – ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical need, will be presenting at Jefferies Global Healthcare …
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH
ERYTECH enters EnterNext© PEA-PME 150 index
SCIENTIFIC CONGRESS – ERYTECH Pharma participates in ASH annual meeting 2014 from December 6 to 9 in San Francisco, CA, USA.
FINANCE – ERYTECH Pharma attends German Equity Forum from November 24 to 26, 2014 in Frankfurt, Germany.
FINANCE – ERYTECH Pharma participates in Actionaria 2014 on November 21 & 22, 2014 in Paris, France.
FINANCE – ERYTECH Pharma takes part in Jefferies Global Healthcare Conference on November 19 & 20, 2014 in London, UK.